Wednesday 28 September 2016

Pharma withheld faulty device info in rivaroxaban trial

Patients must live with uncertainty until concerns over key trial data are addressed

Related items from OnMedica

Extending anticoagulation duration cuts risk of VTE recurrence
Metformin lowers cardiac deaths better than other drugs
US doctor says FDA should have withdrawn rosuvastatin
NICE calls for safer use of controlled drugs
BMJ questions trial evidence for rivaroxaban
via OnMedica News Read More Here.. Lake forest health and fitness http://ift.tt/2dmt7IK

No comments:

Post a Comment